| |
Safety and Efficacy of Dolutegravir and Maraviroc Plus Background Therapy in HIV-1 Treatment-Experienced Participants - BHIVA April 2016
|
| |
| |
from Jules: we know about the DTG mono therapy & DTG+3TC study results & that this approach is being studied in new studies, however the combination of DTG+MVC offers potential because it avoids nukes & PIs, and NNRTIs which may provide metabolic benefits for patients who re older who face non-AIDS comorbidities; some clinicians are already using DTG+MVC for patients who are older and have ART resistance and comorbidities concerns, but this needs to be studied further, and the patient has to be tested to make sure they have CCR5 virus.
Reported by Jules Levin
22nd Annual Conference of the British HIV Association; April 19-22, 2016; Manchester Central, UK
M Prakash,1 J Huang,2 J Lim,3 J Koteff,4 C Trezza,4 S Griffith,4 M Ait-Khaled,1 B Wynne,5 M Gartland,4 A Clark,1 M Aboud1
1ViiV Healthcare, London, UK; 2GlaxoSmithKline, Mississauga, ON, Canada; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Research Triangle Park, NC, USA; 5ViiV Healthcare, Collegeville, PA, USA
SCS/2015: Switch to maraviroc (MVC) + darunavir/ritonavir (DRV/r) in virologically suppressed patients with R5-tropic virus is associated with an excess of virological failures: 48 weeks results of the GUSTA study (10/28/15)
Switch to maraviroc (MVC) + darunavir/ritonavir (DRV/r) in virologically suppressed patients with R5-tropic virus is associated with an excess of virological failures: 48 weeks results of the GUSTA study (10/28/15)
Dolutegravir Monotherapy in HIV-infected Patients with Sustained Viral Suppression: A 24-week Pilot Study (10/27/15)
Dolutegravir monotherapy in patients with suppressed HIV viremia. (10/26/15)
Dolutegravir-Lamivudine as Initial Therapy in HIV-infected, ARV Naïve Patients: First Results of the PADDLE Study - (10/23/15)
Reported by Jules Levin
M Prakash,1 J Huang,2 J Lim,3 J Koteff,4 C Trezza,4 S Griffith,4 M Ait-Khaled,1 B Wynne,5 M Gartland,4 A Clark,1 M Aboud1
1ViiV Healthcare, London, UK; 2GlaxoSmithKline, Mississauga, ON, Canada; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Research Triangle Park, NC, USA; 5ViiV Healthcare, Collegeville, PA, USA
|
|
| |
| |
|
|
|
